Phase II study of combination chemotherapy in treating pediatric patients with newly diagnosed intracranial germinoma

Phase II study of combination chemotherapy in treating pediatric patients with newly diagnosed intracranial germinoma - Combination chemotherapy in treating pediatric patients with intracranial germinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002397

Enrollment

Registered

2009-08-28

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cranial germinoma

Interventions

Germinoma: Patients receive chemotherapy consisting of etoposide and cisplatin. Chemotherapy repeats every 3 weeks for 4 courses. Radiation doses are 24 Gy to the primary site. Germinoma with STGC: P

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of 1 of the following, germinoma, germinoma with STGC. 2. AFP < upper limit of normal, beta hCG < 50 ng/ml. 3. Has undergone biopsy within the past 42 days. 4. No prior radiation therapy or chemotherapy. 5. PS score: 0-3. 6. WBC >2000/mm3, ANC >1000/mm3, Platelet count >100000/mm3 7. ALT <100 IU/ml, Billirubin <1.5 mg/dl, Serum creatinine < upper limit of normal. 8. Normal electorocardiogram.

Exclusion criteria

Exclusion criteria: Has double cancer. Has cardiac disease for which treatment is necessary.

Design outcomes

Primary

Measure	Time frame
3-year progression-free survival	—

Secondary

Measure	Time frame
3-year overall survival	—

Countries

Japan

Contacts

Public ContactKeiko Okada

Osaka City General Hospital Pediatric Hematology/Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026